GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Pharma-Bio Serv Inc (OTCPK:PBSV) » Definitions » Piotroski F-Score

Pharma-Bio Serv (Pharma-Bio Serv) Piotroski F-Score : 5 (As of May. 27, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Pharma-Bio Serv Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Pharma-Bio Serv has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Pharma-Bio Serv's Piotroski F-Score or its related term are showing as below:

PBSV' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 5   Max: 9
Current: 5

During the past 13 years, the highest Piotroski F-Score of Pharma-Bio Serv was 9. The lowest was 3. And the median was 5.


Pharma-Bio Serv Piotroski F-Score Historical Data

The historical data trend for Pharma-Bio Serv's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharma-Bio Serv Piotroski F-Score Chart

Pharma-Bio Serv Annual Data
Trend Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.00 5.00 4.00 7.00 8.00

Pharma-Bio Serv Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.00 7.00 7.00 8.00 5.00

Competitive Comparison of Pharma-Bio Serv's Piotroski F-Score

For the Health Information Services subindustry, Pharma-Bio Serv's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharma-Bio Serv's Piotroski F-Score Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Pharma-Bio Serv's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Pharma-Bio Serv's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jan24) TTM:Last Year (Jan23) TTM:
Net Income was 0.405 + 0.526 + -0.047 + -0.271 = $0.61 Mil.
Cash Flow from Operations was -0.25 + 0.957 + 0.308 + 0.726 = $1.74 Mil.
Revenue was 4.563 + 4.577 + 3.598 + 2.38 = $15.12 Mil.
Gross Profit was 1.346 + 1.55 + 0.93 + 0.536 = $4.36 Mil.
Average Total Assets from the begining of this year (Jan23)
to the end of this year (Jan24) was
(20.9 + 19.618 + 20.297 + 19.902 + 19.231) / 5 = $19.9896 Mil.
Total Assets at the begining of this year (Jan23) was $20.90 Mil.
Long-Term Debt & Capital Lease Obligation was $0.15 Mil.
Total Current Assets was $18.78 Mil.
Total Current Liabilities was $3.68 Mil.
Net Income was 0.24 + 0.288 + 0.173 + 0.426 = $1.13 Mil.

Revenue was 4.967 + 4.774 + 4.638 + 4.238 = $18.62 Mil.
Gross Profit was 1.216 + 1.312 + 1.109 + 1.24 = $4.88 Mil.
Average Total Assets from the begining of last year (Jan22)
to the end of last year (Jan23) was
(22.074 + 20.161 + 20.329 + 20.651 + 20.9) / 5 = $20.823 Mil.
Total Assets at the begining of last year (Jan22) was $22.07 Mil.
Long-Term Debt & Capital Lease Obligation was $0.31 Mil.
Total Current Assets was $20.24 Mil.
Total Current Liabilities was $1.96 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Pharma-Bio Serv's current Net Income (TTM) was 0.61. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Pharma-Bio Serv's current Cash Flow from Operations (TTM) was 1.74. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Jan23)
=0.613/20.9
=0.02933014

ROA (Last Year)=Net Income/Total Assets (Jan22)
=1.127/22.074
=0.05105554

Pharma-Bio Serv's return on assets of this year was 0.02933014. Pharma-Bio Serv's return on assets of last year was 0.05105554. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Pharma-Bio Serv's current Net Income (TTM) was 0.61. Pharma-Bio Serv's current Cash Flow from Operations (TTM) was 1.74. ==> 1.74 > 0.61 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Jan24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jan23 to Jan24
=0.154/19.9896
=0.00770401

Gearing (Last Year: Jan23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jan22 to Jan23
=0.31/20.823
=0.01488738

Pharma-Bio Serv's gearing of this year was 0.00770401. Pharma-Bio Serv's gearing of last year was 0.01488738. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Jan24)=Total Current Assets/Total Current Liabilities
=18.775/3.678
=5.10467645

Current Ratio (Last Year: Jan23)=Total Current Assets/Total Current Liabilities
=20.236/1.961
=10.31922489

Pharma-Bio Serv's current ratio of this year was 5.10467645. Pharma-Bio Serv's current ratio of last year was 10.31922489. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Pharma-Bio Serv's number of shares in issue this year was 22.986. Pharma-Bio Serv's number of shares in issue last year was 22.958. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=4.362/15.118
=0.28853023

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=4.877/18.617
=0.26196487

Pharma-Bio Serv's gross margin of this year was 0.28853023. Pharma-Bio Serv's gross margin of last year was 0.26196487. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Jan23)
=15.118/20.9
=0.72334928

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Jan22)
=18.617/22.074
=0.84339041

Pharma-Bio Serv's asset turnover of this year was 0.72334928. Pharma-Bio Serv's asset turnover of last year was 0.84339041. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+1+1+0+0+1+0
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Pharma-Bio Serv has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Pharma-Bio Serv  (OTCPK:PBSV) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Pharma-Bio Serv Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Pharma-Bio Serv's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharma-Bio Serv (Pharma-Bio Serv) Business Description

Traded in Other Exchanges
N/A
Address
No. 6 Road 696, Pharma-Bio Serv Building, Dorado, PRI, 00646
Pharma-Bio Serv Inc is a compliance and technology transfer services consulting firm. It also provides microbiological testing services and chemical testing services through its laboratory testing facility in Puerto Rico. It has three reportable segments: Puerto Rico technical compliance consulting which is the key revenue driver; United States technical compliance consulting; and Europe technical compliance consulting. The company offers solutions to the pharmaceutical, chemical, biotechnology, medical devices, cosmetic and food industries, and allied products companies.
Executives
Elizabeth Plaza 10 percent owner 363 DORADO BEACH EAST, DORADO PR 00646
Altura Victor Sanchez officer: President and CEO C/O PHARMA-BIO SERV, INC., 6 ROAD 696, DORADO PR 00646
San Juan Holdings 10 percent owner 255 PONCE DE LEON, SUITE 305 MCS PLAZA, SAN JUAN PR 00917
Pedro J Lasanta officer: Chief Financial Officer 373 MENDEZ VIGO, STE 110, DORADO PR 00646
Dov Perlysky director 2 LAKESIDE DRIVE WEST, LAWRENCE NY 11559
L P Venturetek 10 percent owner C/O DAVID SELENGUT ELLENOFF GROSSMAN, 370 LEXINGTON AVENUE 19TH FLOOR, NEW YORK NY 10017
Barron Partners Lp 10 percent owner 730 FIFTH AVENUE, 25TH FLOOR, NEW YORK NY 10019
Manuel O Morera officer: Chief Financial Officer 373 MENDEZ VIGO, SUITE 110, DORADO PR 00646
Mark A Fazio officer: Exec. Vice President and COO P O BOX 1026 GREEN STREET, PERKASIE PA 18944
Kirk Wheeler Michel director 209 EAST TRYON STREET, HILLSBOROUGH NC 27278
Irving L Wiesen director 1273 NORTH AVENUE, APT 1E 7, NEW ROCHELLE NY 10804
Howard Spindel director 39 BROADWAY SUITE 3300, NEW YORK NY 10028
Nelida Plaza Rodriguez officer: Vice President and Secretary G11 CALLE MADRE PERLA URB, DORADO DEL MAR, DORADO PR 00646
Krovim Llc director, 10 percent owner, officer: Manager P.O. BOX 339, LAWRENCE NY 11559